Abstract
The FDA is obligated to protect human subjects and to ensure that data submitted for clinical trials are obtained ethically, scientifically, and without bias. In addition to issuing guidelines for good clinical practice, the FDA conducts compliance oversight of clinical studies in the United States and internationally through an inspection or audit process. A number of factors have led to migration of clinical trials overseas including lengthy recruitment delays, global disease variation, and costs. The FDA has developed a variety of methods to increase the efficiency of the approval process through international outreach, innovative trials, and information technology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Nasir, A. (2015). The Regulatory Landscape. In: Nasir, A. (eds) Clinical Dermatology Trials 101. Springer, Cham. https://doi.org/10.1007/978-3-319-09027-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-09027-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09026-9
Online ISBN: 978-3-319-09027-6
eBook Packages: MedicineMedicine (R0)